Skip to content
PubMed This is a summary of 49 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 49 referenced papers

Top Authors

Denise M. Adams
Children's Hospital of Philadelphia
Timothy D. Le Cras
Cincinnati Children's Hospital Medical Center
Michio Ozeki
Gifu University
Cameron C. Trenor
Boston Children's Hospital
Toshiyuki Fukao
Gifu University
Charles Griffin McDaniel
Cincinnati Children's Hospital Medical Center
Yi Ji
Sichuan University
Harry P. Kozakewich
Boston Children's Hospital
Siyuan Chen
Sichuan University
Akifumi Nozawa
Tohoku University

Top Institutions

Ranked by publications Top 10 institutions
07
09

Tokyo Metropolitan Children's Medical Center

Tokyo, Japan

10 papers
Contributors Kentaro Matsuoka

References

References (49)
  1. 1

    Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.

    Ozeki M, Fujino A, Matsuoka K, et al.

    Pediatric blood & cancer 2016; (63(5)):832-8 doi:10.1002/pbc.25914.

    PMID: 26806875
  2. 2

    Imaging features of kaposiform lymphangiomatosis.

    Goyal P, Alomari AI, Kozakewich HP, et al.

    Pediatric radiology 2016; (46(9)):1282-90 doi:10.1007/s00247-016-3611-1.

    PMID: 27053281
  3. 3

    Angiopoietins as serum biomarkers for lymphatic anomalies.

    Le Cras TD, Mobberley-Schuman PS, Broering M, et al.

    Angiogenesis 2017; (20(1)):163-173 doi:10.1007/s10456-016-9537-2.

    PMID: 27990590
  4. 4

    What echocardiographic findings suggest a pericardial effusion is causing tamponade?

    Alerhand S, Carter JM

    The American journal of emergency medicine 2019; (37(2)):321-326 doi:10.1016/j.ajem.2018.11.004.

    PMID: 30471929
  5. 5

    A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

    Barclay SF, Inman KW, Luks VL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.

    PMID: 30542204
  6. 6

    Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.

    Rodriguez-Laguna L, Agra N, Ibañez K, et al.

    The Journal of experimental medicine 2019; (216(2)):407-418 doi:10.1084/jem.20181353.

    PMID: 30591517
  7. 7

    Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.

    Ricci KW, Hammill AM, Mobberley-Schuman P, et al.

    Pediatric blood & cancer 2019; (66(5)):e27614 doi:10.1002/pbc.27614.

    PMID: 30672136
  8. 8

    Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).

    Ozeki M, Asada R, Saito AM, et al.

    Regenerative therapy 2019; (10()):84-91 doi:10.1016/j.reth.2018.12.001.

    PMID: 30705924
  9. 9

    The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.

    Ozeki M, Nozawa A, Yasue S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):141 doi:10.1186/s13023-019-1118-1.

    PMID: 31196128
  10. 10

    Potential biomarkers of kaposiform lymphangiomatosis.

    Ozeki M, Nozawa A, Kawamoto N, et al.

    Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.

    PMID: 31207041
  11. 11

    Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

    Ji Y, Chen S, Peng S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.

    PMID: 31277673
  12. 12

    Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

    Ozeki M, Aoki Y, Nozawa A, et al.

    Orphanet journal of rare diseases 2019; (14(1)):215 doi:10.1186/s13023-019-1191-5.

    PMID: 31511039
  13. 13

    Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.

    Iacobas I, Adams DM, Pimpalwar S, et al.

    Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.

    PMID: 31617676
  14. 14

    [Clinical characteristics of Kaposiform lymphangiomatosis: a report of 8 cases].

    Qiu T, Yang KY, Peng SH, et al.

    Zhonghua wai ke za zhi [Chinese journal of surgery] 2019; (57(12)):921-926 doi:10.3760/cma.j.issn.0529-5815.2019.12.010.

    PMID: 31826597
  15. 15

    Kaposiform lymphangiomatosis treated with multimodal therapy improves coagulopathy and reduces blood angiopoietin-2 levels.

    Crane J, Manfredo J, Boscolo E, et al.

    Pediatric blood & cancer 2020; (67(9)):e28529 doi:10.1002/pbc.28529.

    PMID: 32634277
  16. 16

    Thoracic duct embolization in kaposiform lymphangiomatosis.

    Bundy JJ, Ootaki Y, McLean TW, et al.

    Journal of vascular surgery. Venous and lymphatic disorders 2020; (8(5)):864-868 doi:10.1016/j.jvsv.2020.03.013.

    PMID: 32653407
  17. 17

    Sirolimus in the treatment of kaposiform lymphangiomatosis.

    Zhou J, Yang K, Chen S, Ji Y

    Orphanet journal of rare diseases 2021; (16(1)):260 doi:10.1186/s13023-021-01893-3.

    PMID: 34103076
  18. 18

    Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.

    Pedersen S, Larsen KO, Christensen AH, et al.

    Acta oncologica (Stockholm, Sweden) 2022; (61(1)):45-51 doi:10.1080/0284186X.2021.1992010.

    PMID: 34666597
  19. 19

    Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.

    Allen-Rhoades W, Al-Ibraheemi A, Kohorst M, et al.

    Human pathology 2022; (122()):72-81 doi:10.1016/j.humpath.2022.02.010.

    PMID: 35202617
  20. 20

    Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion.

    Koerner T, Patel MD, Pai V, Indramohan G

    BMJ case reports 2022; (15(3)) doi:10.1136/bcr-2021-246250.

    PMID: 35232734
  21. 21

    Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

    Chowers G, Abebe-Campino G, Golan H, et al.

    Pediatric research 2023; (94(6)):1911-1915 doi:10.1038/s41390-022-01986-0.

    PMID: 35246606
  22. 22

    Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.

    Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.

    The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.

    PMID: 35385405
  23. 23

    Pericardial tamponade: A comprehensive emergency medicine and echocardiography review.

    Alerhand S, Adrian RJ, Long B, Avila J

    The American journal of emergency medicine 2022; (58()):159-174 doi:10.1016/j.ajem.2022.05.001.

    PMID: 35696801
  24. 24

    Recurrent haemoptysis: a rare diagnosis of kaposiform lymphangiomatosis and review of literature.

    Fedidat R, Elia A, Hershko A, Fridlender Z

    BMJ case reports 2022; (15(9)) doi:10.1136/bcr-2022-250825.

    PMID: 36171013
  25. 25

    [Complicated lymphatic anomaly: a clinicopathological analysis of four cases].

    Pan BJ, Zhao DC, Zhou WX, Feng RE

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2022; (51(11)):1147-1151 doi:10.3760/cma.j.cn112151-20220825-00728.

    PMID: 36323545
  26. 26

    Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.

    Du Y, Hu YT

    American journal of translational research 2022; (14(12)):8768-8772.

    PMID: 36628254
  27. 27

    Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.

    McDaniel CG, Adams DM, Steele KE, et al.

    Pediatric blood & cancer 2023; (70(4)):e30219 doi:10.1002/pbc.30219.

    PMID: 36683202
  28. 28

    Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics.

    Pereira-Nunes J, Madureira M, Dinis A, et al.

    Journal of investigative medicine high impact case reports 2023; (11()):23247096231166678 doi:10.1177/23247096231166678.

    PMID: 37148180
  29. 29

    How we use angiopoietin-2 in the diagnosis and management of vascular anomalies.

    Engel ER, Le Cras TD, Ricci KW

    Pediatric blood & cancer 2024; (71(5)):e30921 doi:10.1002/pbc.30921.

    PMID: 38439088
  30. 30

    Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease.

    McCarter AL, Dellinger MT

    Journal of vascular anomalies 2023; (4(4)) doi:10.1097/jova.0000000000000070.

    PMID: 38737531
  31. 31

    Lyve1-Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic Mice.

    McDaniel CG, Fox D, Pastura P, et al.

    Pediatric blood & cancer 2025; (72(3)):e31492 doi:10.1002/pbc.31492.

    PMID: 39723841
  32. 32

    Primary splenic involvement in kaposiform lymphangiomatosis: A case report.

    Covil E, Gates R

    International journal of surgery case reports 2025; (127()):110868 doi:10.1016/j.ijscr.2025.110868.

    PMID: 39842283
  33. 33

    Complex lymphatic anomalies.

    Alkhulaifat D, Ramirez-Suarez KI, Otero HJ, et al.

    Pediatric radiology 2025; (55(11)):2348-2355 doi:10.1007/s00247-025-06167-9.

    PMID: 39853393
  34. 34

    Perioperative Considerations for a Patient with Juvenile Idiopathic Scoliosis and Kaposiform Lymphangiomatosis Undergoing Spinal Fusion: A Case Report.

    Avendano JP, Rauf R, Vickers B, et al.

    Journal of orthopaedic case reports 2025; (15(5)):103-108 doi:10.13107/jocr.2025.v15.i05.5572.

    PMID: 40351635
  35. 35

    Updated Classification of Vascular Anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group.

    Goldenberg DC, Vikkula M, Penington A, et al.

    Journal of vascular anomalies 2025; (6(2)) doi:10.1097/JOVA.0000000000000113.

    PMID: 40636925
  36. 36

    Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform Lymphangiomatosis.

    Fox DA, McDaniel CG, Pastura P, Le Cras TD

    Pediatric blood & cancer 2025; (72(11)):e31984 doi:10.1002/pbc.31984.

    PMID: 40879319
  37. 37

    Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.

    Xu Y, Zhou J, Lan Y, Ji Y

    Pediatric blood & cancer 2026; (73(1)):e32119 doi:10.1002/pbc.32119.

    PMID: 41116710
  38. 38

    Hemopericardium Following Norovirus Gastroenteritis in a Child: An Uncommon Presentation.

    Hamed M, Karuppaswamy V

    Cureus 2025; (17(10)):e93767 doi:10.7759/cureus.93767.

    PMID: 41189868
  39. 39

    Complex Lymphatic Anomalies: A Comprehensive Review of Imaging Features and Diagnostic Considerations.

    Pratt M, Dillenbeck J, Pimpalwar S, et al.

    Seminars in roentgenology 2026; (62()):150967 doi:10.1016/j.ro.2025.150967.

    PMID: 41349185
  40. 40

    MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

    Alharbi S, Wagner A, Merkle S, et al.

    Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.

    PMID: 41496696
  41. 41

    Trametinib normalizes angiopoietin-2 levels and successfully treats kaposiform lymphangiomatosis.

    McDaniel CG, Merkle S, Lacuna S, et al.

    Journal of vascular anomalies 2025; (6(4)) doi:10.1097/jova.0000000000000124.

    PMID: 41788185
  42. 42

    Imaging of complex lymphatic anomalies in children.

    Klein WM, Biko DM, Gerwins P, Petit P

    Pediatric radiology 2026; doi:10.1007/s00247-026-06608-z.

    PMID: 42024244
  43. 43

    Kaposiform vascular tumors with Kasabach-Merritt phenomenon: a case series of KHE and KLA from a tertiary care center in India.

    Swaminathan VV, Ramasamy A, Veerachamy A, et al.

    European journal of pediatrics 2026; (185(5)).

    PMID: 42033477
  44. 44

    Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.

    Bilny-Paluch M, Piekarczyk P, Błasińska K, et al.

    Frontiers in medicine 2026; (13()):1705297 doi:10.3389/fmed.2026.1705297.

    PMID: 42110416
  45. 45

    Long-term low-dose sirolimus therapy and successful discontinuation in an adult with kaposiform lymphangiomatosis and disseminated intravascular coagulation: a case report.

    Liu J, Xu W, Jiang Q, Xu KF

    Frontiers in medicine 2026; (13()):1852990 doi:10.3389/fmed.2026.1852990.

    PMID: 42266937
  46. 46

    NRAS mutation in a central conducting lymphatic anomaly and PPFIBP1::ROS1 fusion in a Gorham-stout disease patient.

    Yang G, Ren H, Wang J, et al.

    Human molecular genetics 2026; (35(16)) doi:10.1093/hmg/ddag070.

    PMID: 42544506
  47. 47

    Interventional embolization for hemorrhagic pleural effusion in an infant with kaposiform lymphangiomatosis: a case report.

    Li J, Wang R, Liu C, Liu L

    Frontiers in medicine 2026; (13()):1865353 doi:10.3389/fmed.2026.1865353.

    PMID: 42597147
  48. 48

    Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

    Brown G, McNab S, Keogh S, et al.

    Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.

    PMID: 42639465
  49. 49

    Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.

    Khouri C, Bibollet A, Bouchoucha Y, et al.

    European journal of cancer (Oxford, England : 1990) 2026; (248()):117450 doi:10.1016/j.ejca.2026.117450.

    PMID: 42858621